Effectiveness of Mirikizumab in clinical treatment

As an innovative therapeutic drug, Milikizumab (Mirikizumab) has demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis in clinical studies in recent years. Numerous clinical trials have evaluated the drug's effectiveness in situations where other treatments have been ineffective or the side effects are unacceptable.

In the first pivotal study, a total of1,162 participants received an 8-week infusion of Omvoh at the recommended dose. After 12 weeks, results showed that 24% of patients treated with Omvoh achieved clinical remission, with symptoms and signs significantly improving or disappearing. In the placebo group, only 13% achieved clinical remission. The study used the modified Mayo score (MMS) system for evaluation, which takes into account stool frequency, rectal bleeding and endoscopically observed changes in intestinal inflammation to comprehensively reflect the improvement of the patient's condition.

The second study conducted an in-depth analysis of 544 patients who showed good responses in the first study, focusing on the effect of maintenance treatment with subcutaneous injections every 4 weeks. After 40 weeks of follow-up, approximately 50% of patients receiving Omvoh maintenance therapy achieved clinical remission, compared with only 25% of patients in the placebo group. This result shows that continued maintenance therapy significantly improves the clinical response rate of patients, further confirming the effectiveness of militizumab in treatment.

In summary, militizumab has demonstrated significant clinical effects in the treatment of moderately to severely active ulcerative colitis, especially when other treatments are ineffective, demonstrating its good application potential.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/omvoh